Displaying drugs 8351 - 8375 of 12121 in total
Uproleselan
Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML).
Investigational
Matched Iupac: … ]oxy}-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}propanoic acid ... (2S)-3-cyclohexyl-2-{[(2R,3R,4R,5R,6R)-2-{[(1R,2R,3S,5R)-5-{[2-(2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaoctatriacontan ... -38-amido)ethyl]carbamoyl}-3-ethyl-2-{[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}cyclohexyl …
Lilotomab
Lilotomab is under investigation in clinical trial NCT01796171 (A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-hodgkin Lymphoma).
Investigational
Matched Description: … Lilotomab is under investigation in clinical trial NCT01796171 (A Phase 1/2 Study of Betalutin for Treatment …
ALKS 29
ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
Investigational
GEM-231
GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase. A monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types...
Investigational
DDP-200
DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.
Investigational
AMG-222
Investigational
Matched Iupac: … 2-[(2S)-2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)propyl]-N6,N6,N13,N13-tetramethyl-2-(2H- ... 1,2,3,4-tetrazol-5-yl)tricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaene-6,13-dicarboxamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
TAK-243
TAK-243 is under investigation in clinical trial NCT03816319 (TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia).
Investigational
Matched Iupac: … [(1R,2R,3S,4R)-2,3-dihydroxy-4-[(2-{3-[(trifluoromethyl)sulfanyl]phenyl}pyrazolo[1,5-a]pyrimidin-7-yl …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
MK-2748
MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).
Investigational
Matched Iupac: … (1R,18R,22R,26S,29S)-26-cyclopentyl-N-[(1R,2S)-2-ethenyl-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl} …
PT-2385
PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).
Investigational
Matched Iupac: … 3-{[(1S)-2,2-difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1H-inden-4-yl]oxy}-5-fluorobenzonitrile …
MDX-210
Investigational
LP-2307
LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Investigational
OCE-205
Investigational
LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
EDI-200
EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
Investigational
MK-2225
Investigational
HMI-204
HMI-204 is an adeno-associated virus serotype HSC15 expressing human arylsulfatase A
Investigational
RGX-202
RGX-202 is a recombinant AAV8 that contains a vector genome encoding a miniaturized dystrophin protein (microdystrophin).
Investigational
TRK-250
TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.
Investigational
Matched Description: … TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1 …
JE-2147
Experimental
Matched Iupac: … (4R)-3-[(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-phenylbutanoyl]-5,5-dimethyl-N-[( ... 2-methylphenyl)methyl]-1,3-thiazolidine-4-carboxamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
NS-2359
NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal...
Investigational
Matched Iupac: … (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane …
RAF-265
Investigational
Matched Iupac: … 1-methyl-5-({2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl}oxy)-N-[4-(trifluoromethyl)phenyl]- ... 1H-1,3-benzodiazol-2-amine …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
DTS-201
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment.
DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
FAV-201
FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
Investigational
Displaying drugs 8351 - 8375 of 12121 in total